Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

The share prices of Chinese concept stocks suffered a heavy blow, while pharmaceutical stocks soared. Is a wave of "privatization" returning to the market brewing? First generic! Hausen's ...